BURKITT LYMPHOMA

This study is testing a stem cell transplant from a partially matched family donor for patients with hard-to-treat blood cancers like leukemia and lymphoma. Before the transplant, patients receive chemotherapy and radiation to wipe out their own bone marrow and cancer cells. The …

This study is testing the safety and effectiveness of a combination of five targeted drugs (called ViPOR) for adults whose B-cell lymphoma has come back or not improved after prior treatment. The goal is to see if this drug mix can control the cancer. Participants will receive th…

This early-stage study is testing whether adding the drug pomalidomide to standard chemotherapy (with or without rituximab) is safe and tolerable for adults with HIV and aggressive B-cell lymphomas. The main goal is to find the highest dose that doesn't cause severe side effects.…

This early-phase trial is testing a combination treatment for adults with B-cell lymphomas that have come back or stopped responding to standard therapies. The approach involves giving patients a daily oral drug (pirtobrutinib) before and after an infusion of their own geneticall…

This study is testing whether adding a new immunotherapy drug called epcoritamab to a standard chemotherapy regimen (EPOCH-R) is safe and more effective for treating aggressive B-cell lymphomas. The trial will enroll about 18 adults who have not yet received treatment for their s…

This early-stage trial is testing a new drug called pidnarulex (CX-5461) in adults with aggressive, hard-to-treat B-cell lymphomas that have a specific genetic feature called MYC aberration. The main goals are to find the safest and most effective dose and to see if the drug can …

This early-stage study is testing a new combination of six different targeted drugs for adults whose B-cell lymphoma has come back or hasn't responded to previous treatment. The main goal is to find the safest dose of this combination and see if it can help control the cancer. Re…

This early-stage study is testing a new, one-time gene therapy called VNX-101 for patients whose B-cell blood cancers have returned or not responded to other treatments. The therapy is designed to help the patient's own immune system continuously fight cancer cells. Researchers w…

This study is testing a new method to help patients recover their immune systems faster after a stem cell transplant for leukemia. It involves giving patients a special, filtered portion of their donor's immune cells, aiming to reduce the risk of life-threatening viral and fungal…

This study is testing a new drug called zilovertamab vedotin in children and young adults whose cancers have come back or haven't responded to standard treatments. It will enroll about 90 participants aged 1 year and older with specific blood cancers or solid tumors. The main goa…

This is a first-in-human study to test the safety of a new oral drug called SGR-1505 in adults with various types of relapsed or hard-to-treat B-cell cancers, like non-Hodgkin lymphoma and chronic lymphocytic leukemia. The main goal is to find the highest dose patients can tolera…

This study aims to improve treatment for children with Burkitt's lymphoma across Africa. It focuses on catching the disease earlier, monitoring how well treatments work, and adjusting plans quickly if needed. The study will also test adding a medication called rituximab to the st…

This is an early-stage study testing the safety of a personalized cell therapy for adults with specific types of non-Hodgkin lymphoma that have come back or not responded to standard treatments. Doctors will modify a patient's own immune cells to better target and fight their can…

This study aims to understand how a cancer drug called venetoclax works in the body when it's given as a liquid made from crushed tablets. It will enroll up to 30 children and young adults with blood cancers who are already receiving this liquid form because they cannot swallow p…

This study aims to monitor the long-term health of 500 patients who have already received CAR-T cell therapy for various blood cancers in earlier trials. Researchers will follow these patients for up to 15 years to check for any late-developing side effects, such as new cancers o…